Sanofi, GlaxoSmithKline under investigation for possible carcinogen in Zantac

More posts on pharmacy:25% of diabetes clients allocating treatments amid pandemic, survey findsBan disruptive music in drug ads, customers advocates prompt FDAUS to pay Sanofi, GlaxoSmithKline approximately $2.1 B for development, 100M doses of coronavirus vaccine.

The U.S. Justice Department launched an examination into whether Sanofi and GlaxoSmithKline stopped working to report info about a potential carcinogen to the federal government, according to STAT.

In different filings with the U.S. Securities and Exchange Commission, both drugmakers on July 29 said they received civil investigative demands from the Justice Department seeking information on NDMA, an organic chemical utilized in variations of the typical heartburn drug ranitidine, likewise known by the brand name as Zantac.

The levels of NDMA, which was as soon as utilized to develop rocket fuel, can considerably increase if saved in conditions hotter than room temperature. The World Health Organization and the Environmental Protection Agency think about the active ingredient to be a prospective carcinogen.

Katie Adams –
Monday, August 3rd, 2020
Print|Email.

© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this material? View our policies by click on this link.